Clinical trials
Venous Thrombosis trials in France with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Recruiting | 5 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | 2 |
| Centre Hospitalier Universitaire de Nīmes | 2 |
| Centre Hospitalier Universitaire, Amiens | 2 |
| University Hospital, Brest | 2 |
| University Hospital, Montpellier | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Laboratoires Innothera | 1 |
| University Hospital, Bordeaux | 1 |
| University Hospital, Caen | 1 |
| University Hospital, Geneva | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Venous Thrombosis | 18 |
| Postthrombotic Syndrome | 4 |
| Pulmonary Embolism | 3 |
| Thrombosis | 3 |
| Venous Thromboembolism | 2 |
| Atrial Fibrillation | 1 |
| Embolism and Thrombosis | 1 |
| Intermittent Claudication | 1 |
| Myotonic Dystrophy | 1 |
| Recurrence | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.